New Virus-Based therapy takes on Hard-to-Treat cancers
NCT ID NCT04336241
First seen Nov 01, 2025 · Last updated May 16, 2026 · Updated 25 times
Summary
This early-stage study tests a new drug, RP2, in 36 adults with advanced solid tumors that have not responded to standard treatments. The goal is to find the safest dose and see if RP2 works better when combined with another immunotherapy. The study focuses on safety and tumor response, not a cure.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Churchill Hospital
Oxford, OX3 9DU, United Kingdom
-
Hospital Clinico de Valencia
Valencia, 46010, Spain
-
Hospital Universitario HM Sanchinarro
Madrid, 10 28050, Spain
-
Hospital Universitario d'Hebron
Barcelona, 119 08035, Spain
-
The Clatterbridge Cancer Centre NHS Foundation Trust
Bebington, Merseyside, CH63 4JY, United Kingdom
-
The Royal Marsden NHS Foundation Trust
London, SW3 6JJ, United Kingdom
Conditions
Explore the condition pages connected to this study.